📉 Wockhardt Ke Numbers Bol Rahe Hain!
Yaar, Wockhardt ka Q3 FY26 ka result dekh ke asli traders toh khush ho jayenge! Standalone basis par baat karein toh revenue mein 32.3% ki zabardast tezi aayi hai, jo ₹325 Cr se badh kar ₹430 Cr ho gaya. Aur sabse badi khabar? Standalone net profit loss se nikal kar ₹28 Cr par pahunch gaya, jabki pichhle saal isi time ₹22 Cr ka loss tha! Standalone EPS bhi ₹1.73 ho gaya.
Nine months ki baat karein toh standalone revenue 16.8% badh kar ₹1,223 Cr ho gaya aur net profit toh ₹150 Cr par pahunch gaya, pichhle saal ke ₹52 Cr loss se recovery dekhne layak hai. Standalone EPS ab ₹9.24 hai.
Consolidated Scene Kya Hai?
Ab consolidated numbers dekhte hain. Yahaan bhi revenue mein 23.2% ki growth hai, jo ₹721 Cr se ₹888 Cr ho gaya. Aur profit? Bhai, consolidated net profit 205% zordaar jump maar kar ₹20 Cr se ₹61 Cr par chala gaya! Consolidated EPS bhi ₹3.61 ho gaya.
Nine months mein consolidated revenue 6.1% badh kar ₹2,408 Cr ho gaya, aur net profit ₹35 Cr par aa gaya, jabki pichhle saal ₹12 Cr ka loss tha. EPS ₹2.89 ho gaya.
US Business Exit Ka Sachai
Sabse important point ye hai ki company ne strategic decision liya hai ki woh US mein apna generic pharmaceutical business band karegi. Iske liye Morton Grove Pharmaceuticals Inc. aur Wockhardt USA LLC ko voluntarily liquidate kar rahe hain. Is decision ki wajah se nine-month consolidated results mein ₹107 Cr ka exceptional item dikh raha hai, jisme se ₹97 Cr sirf US business exit ka charge hai. Iske alawa ₹10 Cr Indian Labour Codes ke impact ke liye bhi add hue hain.
Toh overall, numbers toh acche hain, especially standalone mein recovery dikh rahi hai, par US exit ka kharcha bhi numbers mein dikh raha hai. Ab aage company kaise perform karti hai, ye dekhna hoga.